contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


acarix-changes-certified-advisor-to-redeye

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Acarix is a diagnostics company. The company has developed a technology that enables the identification of coronary artery disease. The company's product is a non-invasive test that is applied with a patch to the patient to analyze sounds from the heart. The business is conducted primarily within the Nordic market. The company was founded in 2009 as a spin-off from Coloplast. The headquarters are located in Malmö.

Expected SEK 79 million share issue now underway: https://acarix.com/wp-content/uploads/2021/11/acarixpralmeria-prospekteng.pdf

News from America has arrived; I don’t know how to post it here. Thanks in advance

Redeye’s website does have a Disclosures section for the company in question, which states whether Redeye owns the company. In this case, it does not.                   redeye.se              Acarix Disclosures - Redeye    Discover the latest equity research on Acarix.

Tärkeimmät talousuutiset | Kauppalehti – 27 Jun 19              Acarix CADScor®System included in NICE guidelines (UK)    Tärkeimmät ajankohtaiset talousuutiset, pörssikurssit ja kattavat sijoittajapalvelut löydät Kauppalehdestä.                             Here’s a slightly older bulletin. An interesting product, which has been found to be effective and cost-efficient in studies, and is even mentioned in the aforementioned treatment recommendations. It’s an easy-to-use device for clinicians, and in addition to device sales, there’s additional revenue from patient-specific parts/covers. So, there should be potential. But… sales revenue should start coming in so that they don’t run out of money and need a new share issue.

Isn’t that somewhat common? At least I remember seeing Redeye also with other companies as a Certified Adviser. Aren’t there all sorts of companies acting in that role? Edit: From what I quickly found, it’s in at least these:                  Fragbite Group              Certified Adviser - Fragbite Group                             https://www.2curex.com/investors/corporate-governance/certified-adviser/                  sozap.com              Certified Adviser    SOZAP is a digital entertainment company with competence and ambition at its core. We work to create the best gaming experiences in the world.

PubMed              Economic Analysis of the CADScor System for Ruling Out Coronary Artery...    The CADScor System is a potentially cost-saving test for the diagnosis of CAD. When initiated before the use of non-invasive cardiac imaging tests such as computed tomography coronary angiography, the test reduced costs to the healthcare service over...

Interesting that the analyst firm is also an advisor..   Are they also an investor?

Acarix

 Press release Malmö, Sweden October 15, 2020 Acarix changes Certified Advisor to RedeyeAcarix AB (publ) announces today that the company has entered into an agreement with Redeye AB regarding...

Press release Malmö, Sweden October 15, 2020 Acarix changes Certified Advisor to RedeyeAcarix AB (publ) announces today that the company has entered into an agreement with Redeye AB regarding the position as Certified Adviser. Redeye AB will take over as Certified Adviser on October 19, 2020.For further information, please contact: Christian Lindholm, CFO, E-mail: <a href="https://www.globenewswire.com/Tracker?data=xqD-zY120FSnb7-42ZwcPLHU2SV427NMJx5K-nCutkU_wMB7K1ApZ_q9I1aCqa1iQV57UWq3KlqZIuMK7DFSU4dUIoES3neJyI4DIiYPJB1giYTFUIFU1salvK7pI3l3">christian.lindholm@acarix.com</a>, Phone: +46 705 118333This press release has been made public through the agency of the contact person set out above, at the time stated by the Company’s news distributor, GlobeNewswire, at the publication of this press release. About Acarix: Acarix was established in 2009 and is listed on Nasdaq First North Premier Growth Market (ticker: ACARIX). Acarix’s CADScor®System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen. Readout is obtained in less than 10 minutes. Safe and suitable for use in both out- and inpatient settings, the CADScor®System thus has the potential to play a major role in patient triage, avoiding the need for many patients to undergo stressful invasive diagnostic procedures. Wildeco Ekonomisk Information AB (+46 8 545 271 00, info@wildeco.se) is Certified Adviser to Acarix. For more information please visit <a href="https://www.globenewswire.com/Tracker?data=gN4bGtxXD5YA-SDO1n32ST0nLBO4n9mVMUAP1HRQpN6MmzfjFT_CTL0luzxN5gd-l1n3x1ee8N-pXewtGd-rrA==">www.acarix.com</a>. Attachment<ul> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/df99dc72-30a9-4356-81e5-54d4b46bd8d2">Acarix_changes_CA</a> </li> </ul><img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMDQzMjY1OCM0MDA4MDI2NDAjMjA4MjQ3Mg==" width="1" height="1"/>